Corbus Pharmaceuticals Holdings, Inc. (CRBP) vs Foghorn Therapeutics Inc. (FHTX)
A side-by-side comparison of Corbus Pharmaceuticals Holdings, Inc. and Foghorn Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$5.84HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
FHTX
Foghorn Therapeutics Inc.
$1.96HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
Total return — CRBP vs FHTX
growth of $100 · dividends reinvested · last 6yCRBP -81.3% (-24.3%/yr)FHTX -89.0% (-30.7%/yr)CRBP compounded faster over this window
CRBP FHTX
CRBP vs FHTX: by the numbers
- •FHTX is the larger company ($115M vs $108M market cap).
- •Both run net losses; CRBP's is the smaller (0.00% vs -175.78% net margin).
Metrics side by side
Valuation
| Metric | CRBP | FHTX |
|---|---|---|
| P/S ratio | N/A | 3.13 |
| P/B ratio | 1.06 | N/A |
Profitability
| Metric | CRBP | FHTX |
|---|---|---|
| Gross margin | 0.00% | 89.22% |
| Operating margin | 0.00% | -265.64% |
| Net margin | 0.00% | -175.78% |
| ROE | -99.67% | N/A |
| ROIC | -101.30% | -44.81% |
Growth (annualized)
| Metric | CRBP | FHTX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 105.83% |
| Total return CAGR (5Y) | -28.32% | -31.87% |
Frequently asked
- How have CRBP and FHTX total returns compared?
- Over the past 5 years, CRBP delivered -28.32% and FHTX delivered -31.87% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Corbus Pharmaceuticals ROEFoghorn Therapeutics ROECorbus Pharmaceuticals operating marginFoghorn Therapeutics operating marginCorbus Pharmaceuticals revenue growthFoghorn Therapeutics revenue growthCorbus Pharmaceuticals free cash flowFoghorn Therapeutics free cash flow
Corbus Pharmaceuticals & Foghorn Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.